The hormonal and immunological changes in pregnancy have a key role in maintaining maternal tolerance of the semiallogeneic foetus. These pregnancy-associated changes may also influence the course of maternal autoimmune diseases. Noninfectious uveitis tends to improve during pregnancy. Specifically, uveitis activity tends to ameliorate from the second trimester onwards, with the third trimester being associated with the lowest disease activity. The mechanism behind this phenomenon is likely to be multifactorial and complex. Possible mechanisms include Th1/Th2 immunomodulation, regulatory T-cell phenotype plasticity, and immunosuppressive cytokines. This clearly has management implications for patients with chronic sight threatening disease requiring systemic treatment, as most medications are not recommended during pregnancy due to lack of safety data or proven teratogenicity. Given that uveitis activity is expected to decrease in pregnancy, systemic immunosuppressants could be tapered during pregnancy in these patients, with flare-ups being managed with local corticosteroids till delivery. In the postpartum period, as uveitis activity is expected to rebound, patients should be reviewed closely and systemic medications recommenced, depending on uveitis activity and the patient’s breastfeeding status. This review highlights the current understanding of the course of uveitis in pregnancy and its management to help guide clinicians in managing their uveitis patients during this special time in life. 1. Introduction Pregnancy is associated with various hormonal and immunological changes that facilitate the survival of the semiallogeneic foetus. These physiological changes influence the course of various maternal autoimmune diseases [1, 2]. The effect of pregnancy on noninfectious uveitis has not been as extensively studied; however, to date it has been well described by a few authors. It is essential to understand the course of uveitis in pregnancy as uveitis has a peak incidence in young adults and it is not uncommon for female patients with known uveitis to become pregnant. This review will examine the literature on the course of uveitis in pregnancy and its management. This summary would hopefully help guide clinicians in the management of uveitis during pregnancy and the postpartum period. 2. Theories on How Pregnancy Influences Uveitis During pregnancy, the tolerance of the semiallogeneic foetus is made possible by the various hormonal and immunological changes in pregnancy. These physiological changes also have a role in influencing the course of
References
[1]
J. P. Buyon, J. L. Nelson, and M. D. Lockshin, “The effects of pregnancy on autoimmune diseases,” Clinical Immunology and Immunopathology, vol. 78, no. 2, pp. 99–104, 1996.
[2]
R. L. Wilder, “Hormones, pregnancy, and autoimmune diseases,” Annals of the New York Academy of Sciences, vol. 840, pp. 45–50, 1998.
[3]
J. P. Buyon, “The effects of pregnancy on autoimmune diseases,” Journal of Leukocyte Biology, vol. 63, no. 3, pp. 281–287, 1998.
[4]
A. Doria, L. Iaccarino, S. Arienti et al., “Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases,” Reproductive Toxicology, vol. 22, no. 2, pp. 234–241, 2006.
[5]
I. J. Elenkov, J. Hoffman, and R. L. Wilder, “Does differential neuroendocrine control of cytokine production govern the expression of autoimmune diseases in pregnancy and the postpartum period?” Molecular Medicine Today, vol. 3, no. 9, pp. 379–383, 1997.
[6]
I. J. Elenkov, R. L. Wilder, V. K. Bakalov et al., “IL-12, TNF-α, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 10, pp. 4933–4938, 2001.
[7]
S. O. Keeling and A. E. Oswald, “Pregnancy and rheumatic disease: “by the book” or ‘by the doc’,” Clinical Rheumatology, vol. 28, no. 1, pp. 1–9, 2009.
[8]
L. J. Jara, O. Vera-Lastra, J. M. Miranda, M. Alcala, and J. Alvarez-Nemegyei, “Prolactin in human systemic lupus erythematosus,” Lupus, vol. 10, no. 10, pp. 748–756, 2001.
[9]
M. ？stensen, P. M. Villiger, and F. F？rger, “Interaction of pregnancy and autoimmune rheumatic disease,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A437–A446, 2012.
[10]
C.-C. Chan, G. F. Reed, Y. Kim, E. Agrón, and R. R. Buggage, “A correlation of pregnancy term, disease activity, serum female hormones, and cytokines in uveitis,” British Journal of Ophthalmology, vol. 88, no. 12, pp. 1506–1509, 2004.
[11]
R. K. Agarwal, C.-C. Chan, B. Wiggert, and R. R. Caspi, “Pregnancy ameliorates induction and expression of experimental autoimmune uveitis,” Journal of Immunology, vol. 162, no. 5, pp. 2648–2654, 1999.
[12]
E. F. Foxman, M. Zhang, S. D. Hurst et al., “Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation,” Journal of Immunology, vol. 168, no. 5, pp. 2483–2492, 2002.
[13]
M. Akdis, O. Palomares, W. van de Veen, M. van Splunter, and C. A. Akdis, “TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection,” Journal of Allergy and Clinical Immunology, vol. 129, pp. 1438–1449, 2012.
[14]
E. Bettelli, M. Oukka, and V. K. Kuchroo, “TH-17 cells in the circle of immunity and autoimmunity,” Nature Immunology, vol. 8, no. 4, pp. 345–350, 2007.
[15]
J. Furuzawa-Carballeda, M. I. Vargas-Rojas, and A. R. Cabral, “Autoimmune inflammation from the Th17 perspective,” Autoimmunity Reviews, vol. 6, no. 3, pp. 169–175, 2007.
[16]
M. B. Torchinsky and J. M. Blander, “T helper 17 cells: discovery, function, and physiological trigger,” Cellular and Molecular Life Sciences, vol. 67, no. 9, pp. 1407–1421, 2010.
[17]
J. Ernerudh, G. Berg, and J. Mj？sberg, “Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance,” American Journal of Reproductive Immunology, vol. 66, no. 1, pp. 31–43, 2011.
[18]
C. K. Wong, C. Y. Ho, E. K. Li, and C. W. K. Lam, “Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus,” Lupus, vol. 9, no. 8, pp. 589–593, 2000.
[19]
C. Wang, Y. Tian, B. Lei, et al., “Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease.,” Investigative Ophthalmology & Visual Science, vol. 53, pp. 4668–4675, 2012.
[20]
D. Yen, J. Cheung, H. Scheerens et al., “IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6,” Journal of Clinical Investigation, vol. 116, no. 5, pp. 1310–1316, 2006.
[21]
W. Wang, S. Shao, Z. Jiao, M. Guo, H. Xu, and S. Wang, “The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis,” Rheumatology International, vol. 32, no. 4, pp. 887–893, 2012.
[22]
L. Klotz, S. Burgdorf, I. Dani et al., “The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity,” Journal of Experimental Medicine, vol. 206, no. 10, pp. 2079–2089, 2009.
[23]
G. Toldi, J. Rigó Jr., B. Stenczer, B. Vásárhelyi, and A. Molvarec, “Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia,” American Journal of Reproductive Immunology, vol. 66, no. 3, pp. 223–229, 2011.
[24]
W.-H. Zhu, C.-Z. Lu, Y.-M. Huang, H. Link, and B.-G. Xiao, “A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells,” Multiple Sclerosis, vol. 13, no. 1, pp. 33–40, 2007.
[25]
S. S. Soldan, A. I. A. Retuerto, N. L. Sicotte, and R. R. Voskuhl, “Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol,” Journal of Immunology, vol. 171, no. 11, pp. 6267–6274, 2003.
[26]
Z. Williams, “Inducing tolerance to pregnancy,” The New England Journal of Medicine, vol. 367, pp. 1159–1161, 2012.
[27]
J. M. Lipton and A. Catania, “Anti-inflammatory actions of the neuroimmunomodulator α-MSH,” Immunology Today, vol. 18, no. 3, pp. 140–145, 1997.
[28]
J. M. Lipton, “Modulation of host defense by the neuropeptide α-MSH,” Yale Journal of Biology and Medicine, vol. 63, no. 2, pp. 173–182, 1990.
[29]
J. Harness, A. Cavanagh, H. Morton, and P. McCombe, “A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein,” Journal of the Neurological Sciences, vol. 216, no. 1, pp. 33–41, 2003.
[30]
T. B. Tomasi Jr., “Structure and function of alpha-fetoprotein,” Annual Review of Medicine, vol. 28, pp. 453–465, 1977.
[31]
E. Matsuura, Y. Kang, H. Kitakawa et al., “Modulation of T cell function by alpha-fetoprotein: an in vivo study on porcine thyroid peroxidase-induced experimental autoimmune thyroiditis in transgenic mice producing human alpha-fetoprotein,” Tumor Biology, vol. 20, no. 3, pp. 162–171, 1999.
[32]
S. Vassiliadis, A. Ranella, L. Papadimitriou, A. Makrygiannakis, and I. Athanassakis, “Serum levels of pro- and anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion,” Mediators of Inflammation, vol. 7, no. 2, pp. 69–72, 1998.
[33]
M. Ostensen, R. Lundgren, G. Husby, and O. P. Rekvig, “Studies on humoral immunity in pregnancy: immunoglobulins, alloantibodies and autoantibodies in healthy pregnant women and in pregnant women with rheumatoid disease,” Journal of Clinical and Laboratory Immunology, vol. 11, no. 3, pp. 143–147, 1983.
[34]
C. Taguchi, E. Ikeda, N. Hikita, and M. Mochizuki, “A report of two cases suggesting positive influence of pregnancy on uveitis activity,” Nippon Ganka Gakkai zasshi, vol. 103, no. 1, pp. 66–71, 1999.
[35]
A. Kubicka-Trz？ska, “Endogenous uveitis during pregnancy—a report of 4 cases,” Klinika Oczna, vol. 106, no. 3, pp. 328–331, 2004.
[36]
K. Yamada, K. Kimoto, J. Ikewaki, K. Nakatsuka, and H. Yatsuka, “A case of recurrent uveitis with remission during pregnancies,” Japanese Journal of Clinical Ophthalmology, vol. 57, no. 3, pp. 311–315, 2003.
[37]
P. K. Rabiah and A. T. Vitale, “Noninfectious uveitis and pregnancy,” American Journal of Ophthalmology, vol. 136, no. 1, pp. 91–98, 2003.
[38]
L. I. Kump, R. A. Cervantes-Casta？eda, S. N. Androudi, C. S. Foster, and W. G. Christen, “Patterns of exacerbations of chronic non-infectious uveitis in pregnancy and puerperium,” Ocular Immunology and Inflammation, vol. 14, no. 2, pp. 99–104, 2006.
[39]
N. P. Chiam, A. J. Hall, R. J. Stawell, L. Busija, and L. L. Lim, “The course of uveitis in pregnancy and postpartum,” The British Journal of Ophthalmology, vol. 97, no. 10, pp. 1284–1288, 2013.
[40]
D. A. Jabs, “Epidemiology of uveitis,” Ophthalmic Epidemiology, vol. 15, no. 5, pp. 283–284, 2008.
[41]
J. H. Barrett, P. Brennan, M. Fiddler, and A. Silman, “Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis,” Arthritis & Rheumatism, vol. 43, pp. 1010–1015, 2000.
[42]
J. H. Barrett, P. Brennan, M. Fiddler, and A. J. Silman, “Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy,” Arthritis & Rheumatism, vol. 42, pp. 1219–1227, 1999.
[43]
L. Matera, M. Mori, M. Geuna, S. Buttiglieri, and G. Palestro, “Prolactin in autoimmunity and antitumor defence,” Journal of Neuroimmunology, vol. 109, no. 1, pp. 47–55, 2000.
[44]
S. E. Walker, D. Miller, D. Hill, and G. R. Komatireddy, “Prolactin, a pituitary hormone that modifies immune responses. Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico.,” Lupus, vol. 7, no. 6, pp. 371–375, 1998.
[45]
K. B. Elbourne, D. Keisler, and R. W. McMurray, “Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus,” Lupus, vol. 7, no. 6, pp. 420–427, 1998.
[46]
J. L. Nelson and M. Ostenson, “Pregnancy and rheumatoid arthritis,” Rheumatic Disease Clinics of North America, vol. 23, no. 1, pp. 195–212, 1997.
[47]
M. ？stensen and P. M. Villiger, “Immunology of pregnancy—pregnancy as a remission inducing agent in rheumatoid arthritis,” Transplant Immunology, vol. 9, no. 2–4, pp. 155–160, 2002.
[48]
S. H. Zrour, R. Boumiza, N. Sakly et al., “The impact of pregnancy on rheumatoid arthritis outcome: the role of maternofetal HLA class II disparity,” Joint Bone Spine, vol. 77, no. 1, pp. 36–40, 2010.
[49]
E. Musiej-Nowakowska and R. Ploski, “Pregnancy and early onset pauciarticular juvenile chronic arthritis,” Annals of the Rheumatic Diseases, vol. 58, no. 8, pp. 475–480, 1999.
[50]
M. Ostensen, “Pregnancy in patients with a history of juvenile rheumatoid arthritis,” Arthritis and Rheumatism, vol. 34, no. 7, pp. 881–887, 1991.
[51]
C. Gordon, “Pregnancy and autoimmune diseases,” Best Practice & Research Clinical Rheumatology, vol. 18, pp. 359–379, 2004.
[52]
R. L. Mayock, R. D. Sullivan, R. R. Greening, and R. Jones Jr., “Sarcoidosis and pregnancy,” Journal of the American Medical Association, vol. 164, no. 2, pp. 158–163, 1957.
[53]
D. A. Snyder and H. H. Tessler, “Vogt-Koyanagi-Harada syndrome,” American Journal of Ophthalmology, vol. 90, no. 1, pp. 69–75, 1980.
[54]
L. P. Steahly, “Vogt-Koyanagi-Harada syndrome and pregnancy,” Annals of Ophthalmology, vol. 22, no. 2, pp. 59–62, 1990.
[55]
Z. Friedman, M. Granat, and E. Neumann, “The syndrome of Vogt-Koyanagi-Harada and pregnancy,” Metabolic Ophthalmology, vol. 4, no. 3, pp. 147–149, 1980.
[56]
M. Nohara, K. Norose, and K. Segawa, “Vogt-Koyanagi-Harada disease during pregnancy,” British Journal of Ophthalmology, vol. 79, no. 1, pp. 94–95, 1995.
[57]
M. Doi, H. Matsubara, and Y. Uji, “Vogt-Koyanagi-Harada syndrome in a pregnant patient treated with high-dose systemic corticosteroids,” Acta Ophthalmologica Scandinavica, vol. 78, no. 1, pp. 93–96, 2000.
[58]
N. Miyata, M. Sugita, S. Nakamura et al., “Treatment of Vogt-Koyanagi- Harada's disease during pregnancy,” Japanese Journal of Ophthalmology, vol. 45, no. 2, pp. 177–180, 2001.
[59]
D. Wakefield, A. Abu El-Asrar, and P. McCluskey, “Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy,” Ocular Immunology and Inflammation, vol. 20, pp. 277–287, 2012.
[60]
C. Y. Chung, A. K. H. Kwok, and K. L. Chung, “Use of opthalmic medications during pregnancy,” Hong Kong Medical Journal, vol. 10, no. 3, pp. 191–195, 2004.
[61]
Mycophenolate REMS, “Food and Drug Administration,” 2012, https://www.mycophenolaterems.com/HCPOverview.aspx.
[62]
M. Barbhaiya and B. L. Bermas, “Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy,” Clinical Immunology, vol. 149, pp. 225–235, 2013.
[63]
K. K. Temprano, R. Bandlamudi, and T. L. Moore, “Antirheumatic drugs in pregnancy and lactation,” Seminars in Arthritis and Rheumatism, vol. 35, no. 2, pp. 112–121, 2005.
[64]
A. B. Elliott and E. F. Chakravarty, “Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases,” Women's Health, vol. 6, no. 3, pp. 431–442, 2010.
[65]
M. Petri, “Immunosuppressive drug use in pregnancy,” Autoimmunity, vol. 36, no. 1, pp. 51–56, 2003.
[66]
S. R. J. Taylor, H. Isa, L. Joshi, and S. Lightman, “New developments in corticosteroid therapy for uveitis,” Ophthalmologica, vol. 224, supplement 1, pp. 46–53, 2010.
[67]
P. Ferrante, A. Ramsey, C. Bunce, and S. Lightman, “Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis,” Clinical and Experimental Ophthalmology, vol. 32, no. 6, pp. 563–568, 2004.
[68]
P. Riordan-Eva and S. Lightman, “Orbital floor steroid injections in the treatment of uveitis,” Eye, vol. 8, part 1, pp. 66–69, 1994.
[69]
C. J. Helm and G. N. Holland, “The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis,” American Journal of Ophthalmology, vol. 120, no. 1, pp. 55–64, 1995.
[70]
I. G. M. Duguid, R. L. Ford, S. E. Horgan, H. M. A. Towler, and S. L. Lightman, “Combined orbital floor betamethasone and depot methylprednisolone in uveitis,” Ocular Immunology and Inflammation, vol. 13, no. 1, pp. 19–24, 2005.
[71]
M. L. Dafflon, V. T. Tran, Y. Guex-Crosier, and C. P. Herbort, “Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 237, no. 4, pp. 289–295, 1999.
[72]
V. Tanner, J. J. Kanski, and P. A. Frith, “Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis,” Eye, vol. 12, part 4, pp. 679–685, 1998.
[73]
M. Roesel, M. Gutfleisch, C. Heinz, B. Heimes, B. Zurek-Imhoff, and A. Heiligenhaus, “Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis,” Eye, vol. 23, no. 4, pp. 910–914, 2009.
[74]
S. Raghava, M. Hammond, and U. B. Kompella, “Periocular routes for retinal drug delivery,” Expert Opinion on Drug Delivery, vol. 1, no. 1, pp. 99–114, 2004.
[75]
Y. S. Byun and Y.-H. Park, “Complications and safety profile of posterior subtenon injection of triamcinolone acetonide,” Journal of Ocular Pharmacology and Therapeutics, vol. 25, no. 2, pp. 159–162, 2009.
[76]
M. Roesel, M. Gutfleisch, C. Heinz, B. Heimes, B. Zurek-Imhoff, and A. Heiligenhaus, “Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study,” Ophthalmic Research, vol. 42, no. 2, pp. 81–86, 2009.
[77]
R. J. Antcliff, D. J. Spalton, M. R. Stanford, E. M. Graham, T. J. Fytche, and J. Marshall, “Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study,” Ophthalmology, vol. 108, no. 4, pp. 765–772, 2001.
[78]
S. Young, G. Larkin, M. Branley, and S. Lightman, “Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis,” Clinical and Experimental Ophthalmology, vol. 29, no. 1, pp. 2–6, 2001.
[79]
S. Androudi, E. Letko, M. Meniconi, T. Papadaki, M. Ahmed, and C. S. Foster, “Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema,” Ocular Immunology and Inflammation, vol. 13, no. 2-3, pp. 205–212, 2005.
[80]
R. I. Angunawela, C. J. Heatley, T. H. Williamson et al., “Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome,” Acta Ophthalmologica Scandinavica, vol. 83, no. 5, pp. 595–599, 2005.
[81]
H. Kok, C. Lau, N. Maycock, P. McCluskey, and S. Lightman, “Outcome of intravitreal triamcinolone in uveitis,” Ophthalmology, vol. 112, no. 11, pp. 1916.e1–1916.e7, 2005.
[82]
M. C. Gillies, J. M. Simpson, F. A. Billson et al., “Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial,” Archives of Ophthalmology, vol. 122, no. 3, pp. 336–340, 2004.
[83]
S. Tuncer, S. Yilmaz, M. Urgancioglu, and I. Tugal-Tutkun, “Results of Intravitreal Triamcinolone Acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Beh？et disease,” Journal of Ocular Pharmacology and Therapeutics, vol. 23, no. 4, pp. 395–401, 2007.
[84]
M. Kramer, R. Ehrlich, M. Snir et al., “Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet's disease,” American Journal of Ophthalmology, vol. 138, no. 4, pp. 666–667, 2004.
[85]
M. Karacorlu, B. Mudun, H. Ozdemir, S. A. Karacorlu, and E. Burumcek, “Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Beh？et disease,” American Journal of Ophthalmology, vol. 138, no. 2, pp. 289–291, 2004.
[86]
M. Karacorlu, S. Arf Karacorlu, and H. Ozdemir, “Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome,” European Journal of Ophthalmology, vol. 16, no. 3, pp. 481–483, 2006.
[87]
S. Karacorlu, H. Ozdemir, and M. Karacorlu, “Intravitreal triamcinolone acetonide in serpiginous choroiditis,” Japanese Journal of Ophthalmology, vol. 50, no. 3, pp. 290–291, 2006.
[88]
H. Ozdemir, M. Karacorlu, and S. Karacorlu, “Intravitreal triamcinolone acetonide in sympathetic ophthalmia,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 7, pp. 734–736, 2005.
[89]
R. V. P. Chan, B. D. Seiff, H. A. Lincoff, and D. J. Coleman, “Rapid recovery of sympathetic ophthalmia with treatment augmented by intravitreal steroids,” Retina, vol. 26, no. 2, pp. 243–247, 2006.
[90]
J. B. Jonas, “Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia,” American Journal of Ophthalmology, vol. 137, no. 2, pp. 367–368, 2004.
[91]
J. B. Jonas and U. H. M. Spandau, “Repeated intravitreal triamcinolone acetonide for chronic sympathetic ophthalmia,” Acta Ophthalmologica Scandinavica, vol. 84, no. 3, p. 436, 2006.
[92]
M. Roesel, C. Tappeiner, C. Heinz, J. M. Koch, and A. Heiligenhaus, “Comparison between intravitreal and orbital floor triamcinolone acetonide after phacoemulsification in patients with endogenous uveitis,” American Journal of Ophthalmology, vol. 147, no. 3, pp. 406–412, 2009.
[93]
S. Choudhry and S. Ghosh, “Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema,” Clinical and Experimental Ophthalmology, vol. 35, no. 8, pp. 713–718, 2007.
[94]
A. Sallam, R. M. Comer, J. H. Chang et al., “Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children,” Archives of Ophthalmology, vol. 126, no. 2, pp. 200–205, 2008.
[95]
Y. Tao and J. B. Jonas, “Intravitreal triamcinolone,” Ophthalmologica, vol. 225, no. 1, pp. 1–20, 2011.
[96]
J. H. Kempen, M. M. Altaweel, J. T. Holbrook et al., “Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial,” Ophthalmology, vol. 118, no. 10, pp. 1916–1926, 2011.
[97]
C. Lowder, R. Belfort Jr., S. Lightman et al., “Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis,” Archives of Ophthalmology, vol. 129, no. 5, pp. 545–553, 2011.
[98]
L. L. Lim, J. R. Smith, and J. T. Rosenbaum, “Retisert Bausch & Lomb/control delivery systems,” Current Opinion in Investigational Drugs, vol. 6, no. 11, pp. 1159–1167, 2005.
[99]
M. ？stensen, “Antirheumatic therapy and reproduction. The influence on fertility, pregnancy and breast feeding,” Zeitschrift fur Rheumatologie, vol. 65, no. 3, pp. 217–224, 2006.
[100]
L. Park-Wyllie, P. Mazzotta, A. Pastuszak, et al., “Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies,” Teratology, vol. 62, pp. 385–392, 2000.
[101]
P. A. Rosandich, J. T. Kelley III, and D. L. Conn, “Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers,” Current Opinion in Rheumatology, vol. 16, no. 3, pp. 192–198, 2004.
[102]
P. A. Greenberger, Y. K. Odeh, M. C. Frederiksen, and A. J. Atkinson Jr., “Pharmacokinetics of prednisolone transfer to breast milk,” Clinical Pharmacology and Therapeutics, vol. 53, no. 3, pp. 324–328, 1993.
[103]
L. Ost, G. Wettrell, I. Bjorkhem, and A. Rane, “Prednisolone excretion in human milk,” Journal of Pediatrics, vol. 106, no. 6, pp. 1008–1011, 1985.
[104]
B. N？rg？rd, L. Pedersen, K. Fonager, S. N. Rasmussen, and H. T. S？rensen, “Azathioprine, mercaptopurine and birth outcome: a population-based cohort study,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 6, pp. 827–834, 2003.
[105]
C. Dejaco, C. Mittermaier, W. Reinisch et al., “Azathioprine treatment and male fertility in inflammatory bowel disease,” Gastroenterology, vol. 121, no. 5, pp. 1048–1053, 2001.
[106]
C. B. Coulam, T. P. Moyer, N. S. Jiang, and H. Zincke, “Breast-feeding after renal transplantation,” Transplantation Proceedings, vol. 14, no. 3, pp. 605–609, 1982.
[107]
V. T. Armenti, J. S. Radomski, M. J. Moritz et al., “Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation,” Clinical transplants, pp. 97–105, 2001.
[108]
P. E. Pergola, A. Kancharla, and D. J. Riley, “Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone,” Transplantation, vol. 71, no. 7, pp. 994–997, 2001.
[109]
C. Le Ray, A. Coulomb, E. Elefant, R. Frydman, and F. Audibert, “Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations,” Obstetrics and Gynecology, vol. 103, no. 5, pp. 1091–1094, 2004.
[110]
S. Di Paolo, A. Schena, L. F. Morrone et al., “Immunologic evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipients: analysis of lymphocyte subpopulations and immunoglobulin serum levels,” Transplantation, vol. 69, no. 10, pp. 2049–2054, 2000.
[111]
M. E. Moretti, M. Sgro, D. W. Johnson et al., “Cyclosporine excretion into breast milk,” Transplantation, vol. 75, no. 12, pp. 2144–2146, 2003.
[112]
J. A. Katz, C. Antoni, G. F. Keenan, D. E. Smith, S. J. Jacobs, and G. R. Lichtenstein, “Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis,” American Journal of Gastroenterology, vol. 99, no. 12, pp. 2385–2392, 2004.
[113]
U. Mahadevan, S. Kane, W. J. Sandborn et al., “Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 6, pp. 733–738, 2005.
[114]
B. P. Giroir, K. Peppel, M. Silva, and B. Beutler, “The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors,” European Cytokine Network, vol. 3, no. 6, pp. 533–538, 1992.
[115]
K. L. Hyrich, D. P. M. Symmons, K. D. Watson, and A. J. Silman, “Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register,” Arthritis and Rheumatism, vol. 54, no. 8, pp. 2701–2702, 2006.
[116]
D. J. Wallace and M. H. Weisman, “The use of etanercept and other tumor necrosis factor-α blockers in infertility: it's time to get serious,” Journal of Rheumatology, vol. 30, no. 9, pp. 1897–1899, 2003.
[117]
G. M. Enns, E. Roeder, R. T. Chan, Z. Ali-Khan Catts, V. A. Cox, and M. Golabi, “Apparent cyclophosphamide, (cytoxan) embryopathy: a distinct phenotype?” American Journal of Medical Genetics, vol. 86, pp. 237–241, 1999.
[118]
J. Penso, B. Lippe, R. Ehrlich, and F. G. Smith, “Testicular function in prepubertal and pubertal male patients treated with cyclophosphamide for nephrotic syndrome,” Journal of Pediatrics, vol. 84, no. 6, pp. 831–836, 1974.
[119]
W. H. B. Wallace, S. M. Shalet, M. Lendon, and P. H. Morris-Jones, “Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia,” International Journal of Andrology, vol. 14, no. 5, pp. 312–319, 1991.
[120]
V. Papadakis, E. Vlachopapadopoulou, K. van Syckle, et al., “Gonadal function in young patients successfully treated for Hodgkin disease,” Medical and Pediatric Oncology, vol. 32, pp. 366–372, 1999.
[121]
P. H. Wiernik and J. H. Duncan, “Cyclophosphamide in human milk,” The Lancet, vol. 1, no. 7705, article 912, 1971.
[122]
R. Rahimi, S. Nikfar, A. Rezaie, and M. Abdollahi, “Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis,” Reproductive Toxicology, vol. 25, no. 2, pp. 271–275, 2008.
[123]
B. N？rg？rd, A. E. Czeizel, M. Rockenbauer, J. Olsen, and H. T. S？rensen, “Population-based case control study of the safety of sulfasalazine use during pregnancy,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 4, pp. 483–486, 2001.
[124]
M. Mogadam, W. O. Dobbins III, B. I. Korelitz, and S. W. Ahmed, “Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome,” Gastroenterology, vol. 80, no. 1, pp. 72–76, 1981.
[125]
E. Esbjorner, G. Jarnerot, and L. Wranne, “Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation,” Acta Paediatrica Scandinavica, vol. 76, no. 1, pp. 137–142, 1987.
[126]
G. Jarnerot and M.-B. Into-Malmberg, “Sulphasalazine treatment during breast feeding,” Scandinavian Journal of Gastroenterology, vol. 14, no. 7, pp. 869–871, 1979.
